Saturday 17 October 2026 Export NKTX’s income statement to Excel — free account

Nkarta, Inc.

In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.

1.80 0.13 −6.74%

Follow NKTX

Alert me

Market cap: $138.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.07

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	2	—	—	—	—	1	—	—	—	—

Insider Ownership 22.72%

Capital & Financial Ratios $m

Market Cap 138.24

Revenue —

Net Income (117.32)

Free Cash Flow (93.90)

Net Debt (182.76)

Current Ratio 7.98

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.54

Past 5Y EPS Growth —

This Y EPS Growth (18.32%)

Next Y EPS Growth 9.09%

Next Y revenue growth —

Next 5Y EPS Growth 1.82%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 31.34%

10-year low 10-year high

EV/FCF against its own 10 years 12.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	248	267	276	183
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	253	273	283	188

	2023	2024	2025	Q'26
Payables	4	1	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	23	19	22	24

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(0.56%)	(5.68%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’19	—	0	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(28)	(24)	—	—	—
’25	(30)	(19)	(19)	(22)	(89)
’24	(29)	(22)	(25)	(25)	(100)
’23	(21)	(22)	(20)	(23)	(86)
’22	(18)	(17)	(15)	(7)	(57)
’21	(15)	(17)	(18)	(18)	(68)
’20	(8)	(10)	(12)	(13)	(44)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(29)	(24)	—	—	—
’25	(30)	(19)	(19)	(22)	(90)
’24	(29)	(24)	(25)	(26)	(104)
’23	(26)	(32)	(26)	(30)	(114)
’22	(20)	(19)	(22)	(42)	(104)
’21	(16)	(19)	(20)	(19)	(73)
’20	(11)	(13)	(14)	(14)	(51)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.37)	(0.54)	—	—	—
’25	(0.43)	(0.31)	(0.29)	(0.37)	(1.41)
’24	(0.58)	(0.34)	(0.39)	(0.35)	(1.60)
’23	(0.63)	(0.68)	(0.52)	(0.57)	(2.40)
’22	(0.79)	(0.61)	(0.58)	(0.67)	(2.61)
’21	(0.59)	(0.66)	(0.68)	(0.69)	(2.62)
’20	(5.41)	(30.06)	(0.44)	(0.55)	(5.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	22.46	12.46	5.07	1.28	2.08	1.31	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	79.16	62.71	20.35	6.84	16.24	2.74
People
People	Employees	—	—	—	70	95	136	163	150	157	108
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	7	0	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	100.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	0	(21)	(91)	(86)	(114)	(118)	(109)	(104)
	EBT margin, %	—	—	(4.19)	(18,326.96)	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	0	(21)	(91)	(86)	(114)	(118)	(109)	(104)
	Depreciation	—	—	0	0	2	5	2	(3)	2	5
Per share, $
Per share, $	Revenue	—	—	0.20	0.08	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(0.01)	(14.41)	(5.44)	(2.62)	(2.61)	(2.40)	(1.60)	(1.41)
	Cash flow	—	—	(0.16)	(12.55)	(2.59)	(2.07)	(1.31)	(1.76)	(1.47)	(1.20)
	Capex	—	—	0.00	(1.32)	(0.45)	(0.15)	(1.08)	(0.57)	(0.06)	(0.02)
	Free cash flow	—	—	(0.16)	(13.87)	(3.04)	(2.22)	(2.39)	(2.33)	(1.53)	(1.22)
	Book value	—	—	(0.17)	(17.42)	19.11	7.64	8.53	5.58	6.01	4.22
	Shares, m	—	—	33	1	17	33	44	49	68	74
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	—	—	—	—	—	—
	P/S	—	—	0.00	0.00	—	—	—	—	—	—
	P/B	—	—	0.00	0.00	—	—	—	—	—	—
	EV/Sales	—	—	0.00	0.00	—	—	—	—	—	—
	EV/FCF	—	—	(1.67)	(1.67)	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(5)	(18)	(44)	(68)	(57)	(86)	(100)	(89)
	Capex	—	—	(1)	(2)	(8)	(5)	(47)	(28)	(4)	(1)
	Free cash flow	—	—	(5)	(20)	(51)	(73)	(104)	(114)	(104)	(90)
Balance, $m
Balance, $m	Working capital	—	—	6	29	310	233	339	230	254	260
	Total debt	—	—	13	67	9	12	83	—	—	—
	Net debt	—	—	5	(37)	(315)	(238)	(352)	(248)	(267)	(276)
	Shareholders’ equity	—	—	(5)	(25)	321	251	372	273	408	312
Returns, %
Returns, %	ROA	—	—	(5.72)	(72.65)	(47.33)	(28.15)	(30.48)	(27.59)	(24.72)	(22.99)
	ROIC	—	—	0.00	0.00	(510.42)	(419.43)	(370.55)	(327.87)	(56.98)	(211.53)
	ROE	—	—	1.78	136.51	(61.79)	(30.09)	(36.53)	(36.41)	(31.94)	(28.90)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2019 · latest quarter Jun 2019

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MOLN Molecular Partners AG Sponsored ADR	$143.5M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+23.77% (above 0%: growing)	0.00%	0.00%	Compare
TARA Protara Therapeutics, Inc.	$141.8M	— (loss-making)	—	—	n/m	−28.10% (below 0%: shrinking)	0.00%	0.00%	Compare
ALXO ALX Oncology Holdings Inc.	$138.3M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+31.65% (above 0%: growing)	0.00%	0.00%	Compare
NKTX Nkarta, Inc.	$138.2M	— (loss-making)	—	—	n/m	−29.19% (below 0%: shrinking)	0.00%	0.00%
AVXL Anavex Life Sciences Corp.	$137.2M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%	Compare
KRRO Korro Bio, Inc.	$137.1M	— (loss-making)	— (loss-making)	−86.28% (below 0%: shrinking)	n/m	+12.07% (above 0%: growing)	100.00%	0.00%	Compare
ANTX AN2 Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	+7.91% (above 0%: growing)	0.00%	0.00%	Compare
CUE Cue Biopharma, Inc.	$135.6M	— (loss-making)	— (loss-making)	+166.66% (above 0%: growing)	n/m	−742.65% (below 0%: shrinking)	100.00%	(1,113.30%)	Compare
TLSA Tiziana Life Sciences Ltd	$134.7M	— (loss-making)	—	—	−258.11% (below 0%: shrinking)	+18.03% (above 0%: growing)	0.00%	—	Compare
Median of peers	$137.1M	—	—	−92.57%	—	+15.05%	0.00%	0.00%

All 614 Biotechnology stocks →

Nkarta, Inc. (NKTX) key facts

Nkarta, Inc. (NKTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NKTX traded at $1.80, a market capitalization of $138.2 million.
Return on equity was −28.9% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.